Activity of pradimicin BMS-181184 against Aspergillus spp.
The pradimicins are a new class of antifungal agents with activity against the majority of human fungal pathogens. In this study, the in vitro activity of pradimicin BMS-181184 was investigated against a range of the most common species of Aspergillus. The results were compared with itraconazole and amphotericin B. BMS-181184 was found to be active against most Aspergillus spp., but at higher concentrations than itraconazole and amphotericin B.
Oakley
K L
KL
Department of Medicine, Hope Hospital, Manchester, UK.
Moore
C B
CB
Denning
D W
DW
D000666:Amphotericin B / Q000494:pharmacology; D018943:Anthracyclines; D000903:Antibiotics, Antineoplastic / Q000494:pharmacology*; D000935:Antifungal Agents / Q000494:pharmacology*; D001230:Aspergillus / Q000187:drug effects*; D006801:Humans; D017964:Itraconazole / Q000494:pharmacology; D008826:Microbial Sensitivity Tests; D013045:Species Specificity
D018943:Anthracyclines; D000903:Antibiotics, Antineoplastic; D000935:Antifungal Agents; C077639:3'-hydroxybenanomicin A; D017964:Itraconazole; D000666:Amphotericin B